Effect of cyproterone acetate on alpha1-adrenoceptor subtypes in rat vas deferens

Detalhes bibliográficos
Autor(a) principal: Campos, M. [UNESP]
Data de Publicação: 2003
Outros Autores: Morais, P.L. [UNESP], Pupo, A.S. [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.1590/S0100-879X2003001100015
http://hdl.handle.net/11449/28073
Resumo: Gonadal hormones regulate the expression of alpha1-adrenoceptor subtypes in several tissues. The present study was carried out to determine whether or not cyproterone acetate, an anti-androgenic agent, regulates the alpha1-adrenoceptor subtypes that mediate contractions of the rat vas deferens in response to noradrenaline. The actions of subtype selective alpha1-antagonists were investigated in vas deferens from control and cyproterone acetate-treated rats (10 mg/day, sc, for 7 days). Prazosin (pA2 ~9.5), phentolamine (pA2 ~8.3) and yohimbine (pA2 ~6.7) presented competitive antagonism consistent with activation of alpha1-adrenoceptors in vas deferens from both control and treated rats. The pA2 values estimated for WB 4101 (~9.5), benoxathian (~9.7), 5-methylurapidil (~8.5), indoramin (~8.7) and BMY 7378 (~6.8) indicate that alpha1A-adrenoceptors are involved in the contractions of the vas deferens from control and cyproterone acetate-treated rats. Treatment of the vas deferens from control rats with the alpha1B/alpha1D-adrenoceptor alkylating agent chloroethylclonidine had no effect on noradrenaline contractions, supporting the involvement of the alpha1A-subtype. However, this agent partially inhibited the contractions of vas deferens from cyproterone acetate-treated rats, suggesting involvement of multiple receptor subtypes. To further investigate this, the actions of WB 4101 and chloroethylclonidine were reevaluated in the vas deferens from rats treated with cyproterone acetate for 14 days. In these organs WB 4101 presented complex antagonism characterized by a Schild plot with a slope different from unity (0.65 ± 0.05). After treatment with chloroethylclonidine, the complex antagonism presented by WB 4101 was converted into classical competitive antagonism, consistent with participation of alpha1A-adrenoceptors as well as alpha1B-adrenoceptors. These results suggest that cyproterone acetate induces plasticity in the alpha1-adrenoceptor subtypes involved in the contractions of the vas deferens.
id UNSP_0f2caa69660532cc3f6ce748c051c056
oai_identifier_str oai:repositorio.unesp.br:11449/28073
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Effect of cyproterone acetate on alpha1-adrenoceptor subtypes in rat vas deferensAlpha1-adrenoceptorsVas deferensCyproterone acetateGonadal hormones regulate the expression of alpha1-adrenoceptor subtypes in several tissues. The present study was carried out to determine whether or not cyproterone acetate, an anti-androgenic agent, regulates the alpha1-adrenoceptor subtypes that mediate contractions of the rat vas deferens in response to noradrenaline. The actions of subtype selective alpha1-antagonists were investigated in vas deferens from control and cyproterone acetate-treated rats (10 mg/day, sc, for 7 days). Prazosin (pA2 ~9.5), phentolamine (pA2 ~8.3) and yohimbine (pA2 ~6.7) presented competitive antagonism consistent with activation of alpha1-adrenoceptors in vas deferens from both control and treated rats. The pA2 values estimated for WB 4101 (~9.5), benoxathian (~9.7), 5-methylurapidil (~8.5), indoramin (~8.7) and BMY 7378 (~6.8) indicate that alpha1A-adrenoceptors are involved in the contractions of the vas deferens from control and cyproterone acetate-treated rats. Treatment of the vas deferens from control rats with the alpha1B/alpha1D-adrenoceptor alkylating agent chloroethylclonidine had no effect on noradrenaline contractions, supporting the involvement of the alpha1A-subtype. However, this agent partially inhibited the contractions of vas deferens from cyproterone acetate-treated rats, suggesting involvement of multiple receptor subtypes. To further investigate this, the actions of WB 4101 and chloroethylclonidine were reevaluated in the vas deferens from rats treated with cyproterone acetate for 14 days. In these organs WB 4101 presented complex antagonism characterized by a Schild plot with a slope different from unity (0.65 ± 0.05). After treatment with chloroethylclonidine, the complex antagonism presented by WB 4101 was converted into classical competitive antagonism, consistent with participation of alpha1A-adrenoceptors as well as alpha1B-adrenoceptors. These results suggest that cyproterone acetate induces plasticity in the alpha1-adrenoceptor subtypes involved in the contractions of the vas deferens.Universidade Estadual Paulista Instituto de Biociências Departamento de FarmacologiaUniversidade Estadual Paulista Instituto de Biociências Departamento de FarmacologiaAssociação Brasileira de Divulgação Científica (ABRADIC)Universidade Estadual Paulista (Unesp)Campos, M. [UNESP]Morais, P.L. [UNESP]Pupo, A.S. [UNESP]2014-05-20T15:11:33Z2014-05-20T15:11:33Z2003-11-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1571-1581application/pdfhttp://dx.doi.org/10.1590/S0100-879X2003001100015Brazilian Journal of Medical and Biological Research. Associação Brasileira de Divulgação Científica, v. 36, n. 11, p. 1571-1581, 2003.0100-879Xhttp://hdl.handle.net/11449/2807310.1590/S0100-879X2003001100015S0100-879X2003001100015S0100-879X2003001100015.pdf2224433126054725SciELOreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengBrazilian Journal of Medical and Biological Research1.492info:eu-repo/semantics/openAccess2023-11-13T06:08:26Zoai:repositorio.unesp.br:11449/28073Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-05T17:32:35.055075Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Effect of cyproterone acetate on alpha1-adrenoceptor subtypes in rat vas deferens
title Effect of cyproterone acetate on alpha1-adrenoceptor subtypes in rat vas deferens
spellingShingle Effect of cyproterone acetate on alpha1-adrenoceptor subtypes in rat vas deferens
Campos, M. [UNESP]
Alpha1-adrenoceptors
Vas deferens
Cyproterone acetate
title_short Effect of cyproterone acetate on alpha1-adrenoceptor subtypes in rat vas deferens
title_full Effect of cyproterone acetate on alpha1-adrenoceptor subtypes in rat vas deferens
title_fullStr Effect of cyproterone acetate on alpha1-adrenoceptor subtypes in rat vas deferens
title_full_unstemmed Effect of cyproterone acetate on alpha1-adrenoceptor subtypes in rat vas deferens
title_sort Effect of cyproterone acetate on alpha1-adrenoceptor subtypes in rat vas deferens
author Campos, M. [UNESP]
author_facet Campos, M. [UNESP]
Morais, P.L. [UNESP]
Pupo, A.S. [UNESP]
author_role author
author2 Morais, P.L. [UNESP]
Pupo, A.S. [UNESP]
author2_role author
author
dc.contributor.none.fl_str_mv Universidade Estadual Paulista (Unesp)
dc.contributor.author.fl_str_mv Campos, M. [UNESP]
Morais, P.L. [UNESP]
Pupo, A.S. [UNESP]
dc.subject.por.fl_str_mv Alpha1-adrenoceptors
Vas deferens
Cyproterone acetate
topic Alpha1-adrenoceptors
Vas deferens
Cyproterone acetate
description Gonadal hormones regulate the expression of alpha1-adrenoceptor subtypes in several tissues. The present study was carried out to determine whether or not cyproterone acetate, an anti-androgenic agent, regulates the alpha1-adrenoceptor subtypes that mediate contractions of the rat vas deferens in response to noradrenaline. The actions of subtype selective alpha1-antagonists were investigated in vas deferens from control and cyproterone acetate-treated rats (10 mg/day, sc, for 7 days). Prazosin (pA2 ~9.5), phentolamine (pA2 ~8.3) and yohimbine (pA2 ~6.7) presented competitive antagonism consistent with activation of alpha1-adrenoceptors in vas deferens from both control and treated rats. The pA2 values estimated for WB 4101 (~9.5), benoxathian (~9.7), 5-methylurapidil (~8.5), indoramin (~8.7) and BMY 7378 (~6.8) indicate that alpha1A-adrenoceptors are involved in the contractions of the vas deferens from control and cyproterone acetate-treated rats. Treatment of the vas deferens from control rats with the alpha1B/alpha1D-adrenoceptor alkylating agent chloroethylclonidine had no effect on noradrenaline contractions, supporting the involvement of the alpha1A-subtype. However, this agent partially inhibited the contractions of vas deferens from cyproterone acetate-treated rats, suggesting involvement of multiple receptor subtypes. To further investigate this, the actions of WB 4101 and chloroethylclonidine were reevaluated in the vas deferens from rats treated with cyproterone acetate for 14 days. In these organs WB 4101 presented complex antagonism characterized by a Schild plot with a slope different from unity (0.65 ± 0.05). After treatment with chloroethylclonidine, the complex antagonism presented by WB 4101 was converted into classical competitive antagonism, consistent with participation of alpha1A-adrenoceptors as well as alpha1B-adrenoceptors. These results suggest that cyproterone acetate induces plasticity in the alpha1-adrenoceptor subtypes involved in the contractions of the vas deferens.
publishDate 2003
dc.date.none.fl_str_mv 2003-11-01
2014-05-20T15:11:33Z
2014-05-20T15:11:33Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1590/S0100-879X2003001100015
Brazilian Journal of Medical and Biological Research. Associação Brasileira de Divulgação Científica, v. 36, n. 11, p. 1571-1581, 2003.
0100-879X
http://hdl.handle.net/11449/28073
10.1590/S0100-879X2003001100015
S0100-879X2003001100015
S0100-879X2003001100015.pdf
2224433126054725
url http://dx.doi.org/10.1590/S0100-879X2003001100015
http://hdl.handle.net/11449/28073
identifier_str_mv Brazilian Journal of Medical and Biological Research. Associação Brasileira de Divulgação Científica, v. 36, n. 11, p. 1571-1581, 2003.
0100-879X
10.1590/S0100-879X2003001100015
S0100-879X2003001100015
S0100-879X2003001100015.pdf
2224433126054725
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Brazilian Journal of Medical and Biological Research
1.492
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 1571-1581
application/pdf
dc.publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica (ABRADIC)
publisher.none.fl_str_mv Associação Brasileira de Divulgação Científica (ABRADIC)
dc.source.none.fl_str_mv SciELO
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808128823057711104